4 active not recruiting, 3 terminated, 2 completed, 2 recruiting. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 4, Terminated 3, Completed 2, Recruiting 2 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow ulixertinib: new trials by email Literature Review of ulixertinib trials Research Report on ulixertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis Ulixertinib, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2025-01-07 | 2026-07-28 |
| Ulixertinib in People With Histiocytic Neoplasms Ulixertinib - Histiocytic Neoplasms | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 38 | 2024-05-07 | 2026-10-15 |
| Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Ulixertinib, Hydroxychloroquine - Tumor, Solid, Gastrointestinal Cancer | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 47 | 2022-05-26 | 2025-09-25 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Ulixertinib, Physician's Choice - Advanced Solid Tumor, BRAF Gene Mutation | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 104 | 2021-01-07 | 2024-06-04 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-07-24 | 2026-10-15 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-11-13 |
| A Phase II Study of BVD-523 in Metastatic Uveal Melanoma BVD-523 - Uveal Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 13 | 2018-03-26 | 2026-07-27 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes BVD-523 - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | BioMed Valley Discoveries, Inc | 53 | 2014-11-01 | 2019-01-29 |
| Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies BVD-523 - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | BioMed Valley Discoveries, Inc | 136 | 2013-03-01 | 2020-03-20 |
Glioma (3) · Ependymoma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Multiple Myeloma (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Sarcoma, Ewing (2)
BioMed Valley Discoveries, Inc (4) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (2) · Dana-Farber Cancer Institute (1)
United States (11) · Puerto Rico (3) · Australia (1) · Canada (1) · Guam (1)
Donald W Parsons (1) · Eli Diamond, MD (1) · F. Stephen Hodi, MD (1) · Keith T Flaherty (1) · Kieuhoa T Vo (1) · Raajit Rampal, MD, PhD (1) · Vivek Subbiah (1)
PMID 28939558, PMID 26586415, PMID 29603015, PMID 31401903, PMID 32463741, PMID 33048619, PMID 33389388, PMID 33591402, PMID 35133871, PMID 35138919, PMID 35353553, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38935895, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41166674, PMID 42686334
U10CA180820 (2), U10CA180886 (2), U24CA196172 (1)